Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter) | 78172-2

Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter) | 78172-2 | Gentaur US, UK & Europe Disrtribition

Category: Coronavirus/Lentivirus

Application: N/A

Background: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The B.1.429 variant (also known as CAL.20C) was identified in California in the spring of 2021 and contains a number of mutations. This variant may spread more easily and quickly than other variants.

Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.429 Variant: S13I
W152C
L452R
D614G

Product Type: Lentivirus

Shippement Condition: -80°C